These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 15538607)

  • 1. The prevalence of tardive dyskinesia after a nine month naturalistic randomized trial comparing olanzapine with conventional treatment for schizophrenia and related disorders.
    de Jesus Mari J; Lima MS; Costa AN; Alexandrino N; Rodrigues-Filho S; de Oliveira IR; Tollefson GD
    Eur Arch Psychiatry Clin Neurosci; 2004 Dec; 254(6):356-61. PubMed ID: 15538607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality of life in schizophrenia: a multicenter, randomized, naturalistic, controlled trial comparing olanzapine to first-generation antipsychotics.
    Silva de Lima M; de Jesus Mari J; Breier A; Maria Costa A; Pondé de Sena E; Hotopf M
    J Clin Psychiatry; 2005 Jul; 66(7):831-8. PubMed ID: 16013897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized controlled trial of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced tardive dyskinesia.
    Chan HY; Chiang SC; Chang CJ; Gau SS; Chen JJ; Chen CH; Hwu HG; Lai MS
    J Clin Psychiatry; 2010 Sep; 71(9):1226-33. PubMed ID: 20441726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Olanzapine treatment for tardive dyskinesia in schizophrenia patients: a prospective clinical trial with patients randomized to blinded dose reduction periods.
    Kinon BJ; Jeste DV; Kollack-Walker S; Stauffer V; Liu-Seifert H
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Sep; 28(6):985-96. PubMed ID: 15380859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Tardive dyskinesia in patients with schizophrenia treated with olanzapine - results from a 20-month, prospective, open study under naturalistic conditions].
    Szafrański T
    Psychiatr Pol; 2014; 48(6):1155-65. PubMed ID: 25717485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of olanzapine on tardive dyskinetic symptoms in a state hospital population.
    Brar JS; Parepally H; Chalasani L; Gopalani A; Appel N; Chengappa KN
    Ann Clin Psychiatry; 2008; 20(3):139-44. PubMed ID: 18633740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol.
    Beasley CM; Dellva MA; Tamura RN; Morgenstern H; Glazer WM; Ferguson K; Tollefson GD
    Br J Psychiatry; 1999 Jan; 174():23-30. PubMed ID: 10211147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Belgian Schizophrenia Outcome Survey - results of a 2-year naturalistic study in patients stabilised on monotherapy with olanzapine, risperidone or haloperidol.
    Peuskens J; Gillain B; De Graeve D; Van Vleymen B; Albert A
    Eur Psychiatry; 2009 Apr; 24(3):154-63. PubMed ID: 19118983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol.
    Tollefson GD; Beasley CM; Tamura RN; Tran PV; Potvin JH
    Am J Psychiatry; 1997 Sep; 154(9):1248-54. PubMed ID: 9286184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia.
    Caroff SN; Davis VG; Miller DD; Davis SM; Rosenheck RA; McEvoy JP; Campbell EC; Saltz BL; Riggio S; Chakos MH; Swartz MS; Keefe RS; Stroup TS; Lieberman JA;
    J Clin Psychiatry; 2011 Mar; 72(3):295-303. PubMed ID: 20816031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial.
    Kryzhanovskaya L; Schulz SC; McDougle C; Frazier J; Dittmann R; Robertson-Plouch C; Bauer T; Xu W; Wang W; Carlson J; Tohen M
    J Am Acad Child Adolesc Psychiatry; 2009 Jan; 48(1):60-70. PubMed ID: 19057413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: results from a long-term study.
    Gharabawi GM; Bossie CA; Zhu Y; Mao L; Lasser RA
    Schizophr Res; 2005 Sep; 77(2-3):129-39. PubMed ID: 15913962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Double-blind, randomized comparison of olanzapine versus fluphenazine in the long-term treatment of schizophrenia.
    Dossenbach MR; Folnegovic-Smalc V; Hotujac L; Uglesic B; Tollefson GD; Grundy SL; Friedel P; Jakovljevic MM;
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Mar; 28(2):311-8. PubMed ID: 14751428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.
    Dossenbach M; Erol A; el Mahfoud Kessaci M; Shaheen MO; Sunbol MM; Boland J; Hodge A; O'Halloran RA; Bitter I;
    J Clin Psychiatry; 2004 Mar; 65(3):312-21. PubMed ID: 15096069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Olanzapine in treatment-refractory schizophrenia: results of an open-label study. The Spanish Group for the Study of Olanzapine in Treatment-Refractory Schizophrenia.
    Martín J; Gómez JC; García-Bernardo E; Cuesta M; Alvarez E; Gurpegui M
    J Clin Psychiatry; 1997 Nov; 58(11):479-83. PubMed ID: 9413413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia.
    Kinon BJ; Stauffer VL; Kollack-Walker S; Chen L; Sniadecki J
    J Clin Psychopharmacol; 2008 Dec; 28(6):601-7. PubMed ID: 19011427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.
    Simpson GM; Glick ID; Weiden PJ; Romano SJ; Siu CO
    Am J Psychiatry; 2004 Oct; 161(10):1837-47. PubMed ID: 15465981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study.
    Wang X; Savage R; Borisov A; Rosenberg J; Woolwine B; Tucker M; May R; Feldman J; Nemeroff CB; Miller AH
    J Psychiatr Res; 2006 Oct; 40(7):669-76. PubMed ID: 16762371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia.
    Breier A; Berg PH; Thakore JH; Naber D; Gattaz WF; Cavazzoni P; Walker DJ; Roychowdhury SM; Kane JM
    Am J Psychiatry; 2005 Oct; 162(10):1879-87. PubMed ID: 16199834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial.
    Miller DD; McEvoy JP; Davis SM; Caroff SN; Saltz BL; Chakos MH; Swartz MS; Keefe RS; Rosenheck RA; Stroup TS; Lieberman JA
    Schizophr Res; 2005 Dec; 80(1):33-43. PubMed ID: 16171976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.